Drug intelligence / Profile preview

CF2202

Development stage: Preclinical
Lead developer: Zhongke CELFULL
Administration: Oral

Overview

CF2202 is a mitochondrial-focused nutraceutical candidate developed by Zhongke CELFULL Mitochondrial Medicine, specifically targeting ovary health. It is part of the company's broader pipeline of mitochondrial medicines aimed at addressing age-related cellular decline and metabolic health. The product is currently in the technology development (TechDev) phase, which precedes product development and commercial launch in the company's nutraceutical classification system. As a mitochondrial medicine, it likely aims to support ovarian function by enhancing mitochondrial efficiency or reducing oxidative stress, although specific molecular targets have not been publicly disclosed.

Beyond the preview

Go deeper on CF2202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CF2202.

Explore the full profile